NZ592444A - Vaccine compositions comprising a mutated factor h binding protein - Google Patents

Vaccine compositions comprising a mutated factor h binding protein

Info

Publication number
NZ592444A
NZ592444A NZ592444A NZ59244409A NZ592444A NZ 592444 A NZ592444 A NZ 592444A NZ 592444 A NZ592444 A NZ 592444A NZ 59244409 A NZ59244409 A NZ 59244409A NZ 592444 A NZ592444 A NZ 592444A
Authority
NZ
New Zealand
Prior art keywords
binding protein
factor
vaccine compositions
mutated factor
seq
Prior art date
Application number
NZ592444A
Other languages
English (en)
Inventor
Rachel Exley
Christoph Tang
Susan M Lea
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Priority to NZ601538A priority Critical patent/NZ601538A/en
Publication of NZ592444A publication Critical patent/NZ592444A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ592444A 2008-10-25 2009-10-26 Vaccine compositions comprising a mutated factor h binding protein NZ592444A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ601538A NZ601538A (en) 2008-10-25 2009-10-26 Vaccine compositions comprising a mutated factor h binding protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0819633.9A GB0819633D0 (en) 2008-10-25 2008-10-25 Composition
PCT/GB2009/051439 WO2010046715A1 (en) 2008-10-25 2009-10-26 Vaccine compositions comprising a mutated factor h binding protein

Publications (1)

Publication Number Publication Date
NZ592444A true NZ592444A (en) 2012-11-30

Family

ID=40133849

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ592444A NZ592444A (en) 2008-10-25 2009-10-26 Vaccine compositions comprising a mutated factor h binding protein
NZ601538A NZ601538A (en) 2008-10-25 2009-10-26 Vaccine compositions comprising a mutated factor h binding protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ601538A NZ601538A (en) 2008-10-25 2009-10-26 Vaccine compositions comprising a mutated factor h binding protein

Country Status (23)

Country Link
US (1) US20120052092A1 (enExample)
EP (2) EP3501534B1 (enExample)
JP (2) JP5676458B2 (enExample)
KR (3) KR20170000390A (enExample)
CN (2) CN105412920A (enExample)
AU (1) AU2009306114B2 (enExample)
BR (1) BRPI0919926A2 (enExample)
CA (1) CA2741619A1 (enExample)
CO (1) CO6382140A2 (enExample)
DK (1) DK3501534T5 (enExample)
ES (1) ES2970878T3 (enExample)
FI (1) FI3501534T3 (enExample)
GB (1) GB0819633D0 (enExample)
HR (1) HRP20240226T1 (enExample)
HU (1) HUE065348T2 (enExample)
LT (1) LT3501534T (enExample)
MX (1) MX2011004322A (enExample)
NZ (2) NZ592444A (enExample)
PL (1) PL3501534T3 (enExample)
PT (1) PT3501534T (enExample)
RU (1) RU2559528C2 (enExample)
SI (1) SI3501534T1 (enExample)
WO (1) WO2010046715A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261341A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
EP1860191A3 (en) 1999-05-19 2008-02-13 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
EP2275552B1 (en) 1999-10-29 2015-09-09 GlaxoSmithKline Biologicals SA Neisserial antigenic peptides
CN101139590B (zh) 2000-02-28 2012-07-18 启龙股份公司 奈瑟球菌蛋白质的杂交表达
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
DE60335477D1 (de) 2002-10-11 2011-02-03 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
ES2557282T3 (es) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
ES2797504T3 (es) 2009-03-24 2020-12-02 Glaxosmithkline Biologicals Sa Proteína de enlace del factor H meningocócico utilizada como adyuvante
NZ595361A (en) 2009-04-30 2013-09-27 Childrens Hosp & Res Ct Oak Chimeric factor h binding proteins (fhbp) and methods of use
EP2493499A1 (en) * 2009-10-27 2012-09-05 Novartis AG Modified meningococcal fhbp polypeptides
JP2013521326A (ja) * 2010-03-10 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
BR122021020829B8 (pt) 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
MX2014008988A (es) 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
US10376573B2 (en) 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
AU2013295242C1 (en) 2012-07-27 2018-08-09 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
WO2014140562A1 (en) * 2013-03-14 2014-09-18 Isis Innovation Limited Immunogenic composition to neisseria
CA2918547A1 (en) 2013-08-02 2015-02-05 Peter T. Beernink Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof
CA2940447C (en) 2014-02-28 2023-07-11 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
KR102761870B1 (ko) 2014-07-23 2025-02-05 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 인자 h 결합 단백질 변이체 및 이의 사용 방법
KR102709811B1 (ko) * 2014-08-20 2024-09-24 스티흐팅 산퀸 불드포르지닝 인자 h 강화 항체 및 그의 용도
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
CN113453709A (zh) 2018-12-21 2021-09-28 格里菲斯大学 用于引发免疫应答的组合物、方法和用途
JP2022541757A (ja) * 2019-07-08 2022-09-27 クラポード バイオ，インコーポレイテッド リポオリゴ糖組成物およびワクチンの製造および使用方法
KR20220057530A (ko) 2019-07-17 2022-05-09 제미니 테라퓨틱스 서브, 인코포레이티드 인자 h 강화 항체 및 이의 용도
US12053516B2 (en) 2021-02-19 2024-08-06 Sanofi Pasteur Inc. Meningococcal B recombinant vaccine
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786592A (en) * 1986-06-18 1988-11-22 Scripps Clinic And Research Foundation Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
US5476784A (en) * 1993-04-06 1995-12-19 Rice; Peter A. Gonococcal anti-idiotypic antibodies and methods and compositions using them
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP1618185A4 (en) * 2003-04-16 2009-05-27 Wyeth Corp NEW IMMUNOLOGICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCOULAR DISEASE
DK2682126T3 (en) * 2005-01-27 2017-02-27 Children's Hospital & Res Center At Oakland GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2008001224A2 (en) * 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
BR112012004275A2 (pt) * 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
BR122021020829B8 (pt) * 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada

Also Published As

Publication number Publication date
AU2009306114A1 (en) 2010-04-29
PT3501534T (pt) 2024-02-07
FI3501534T3 (fi) 2024-02-09
GB0819633D0 (en) 2008-12-03
JP2015063558A (ja) 2015-04-09
CN102245202A (zh) 2011-11-16
KR20110092282A (ko) 2011-08-17
JP5676458B2 (ja) 2015-02-25
EP3501534B1 (en) 2023-11-29
JP2012506411A (ja) 2012-03-15
KR20170000390A (ko) 2017-01-02
US20120052092A1 (en) 2012-03-01
BRPI0919926A2 (pt) 2016-02-16
CO6382140A2 (es) 2012-02-15
JP6076326B2 (ja) 2017-02-08
HRP20240226T1 (hr) 2024-05-10
ES2970878T3 (es) 2024-05-31
LT3501534T (lt) 2024-03-12
RU2559528C2 (ru) 2015-08-10
RU2011120706A (ru) 2012-11-27
PL3501534T3 (pl) 2024-04-02
MX2011004322A (es) 2011-06-16
KR20190011836A (ko) 2019-02-07
NZ601538A (en) 2014-01-31
AU2009306114B2 (en) 2015-10-01
DK3501534T3 (da) 2024-02-05
EP3501534A1 (en) 2019-06-26
CA2741619A1 (en) 2010-04-29
EP2355845A1 (en) 2011-08-17
HUE065348T2 (hu) 2024-05-28
SI3501534T1 (sl) 2024-03-29
WO2010046715A1 (en) 2010-04-29
CN105412920A (zh) 2016-03-23
EP2355845B1 (en) 2018-12-05
DK3501534T5 (da) 2024-09-02

Similar Documents

Publication Publication Date Title
NZ592444A (en) Vaccine compositions comprising a mutated factor h binding protein
PH12018501517B1 (en) Neisseria meningitidis compositions and methods thereof
NZ622048A (en) Hybrid polypeptides including meningococcal fhbp sequences
WO2010127172A3 (en) Chimeric factor h binding proteins (fhbp) and methods of use
MX2009006760A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
NZ707439A (en) Modified factor ix polypeptides and uses thereof
NZ607224A (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens
NZ598351A (en) Il-17 binding compounds and medical uses thereof
PE20120425A1 (es) Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga
EP3444352A3 (en) Production of recombinant vaccine in e. coli by enzymatic conjugation
WO2009023300A3 (en) Mutants of cholesterol-dependent cytolysins and uses thereof
NZ604089A (en) Multivalent glycopeptide constructs and uses thereof
MX2014013333A (es) Variantes de enzima quimosina mejoradas.
NZ597923A (en) Protein glycosylation
EP4417256A3 (en) Materials and methods for improving lung function
NZ586430A (en) Mutant forms of streptolysin o (slo)
NZ601488A (en) Immunogenic proteins and compositions
NZ594268A (en) Grass peptides for vaccine
WO2009072555A1 (ja) 癌ワクチン
NZ614064A (en) Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
PH12013502292A1 (en) Protein f - a novel haemophilus influenzae adhesin with laminin and vitronectin binding properties
NZ593200A (en) Peptide adjuvants
AU2011350442B2 (en) Modified tamavidin
GB201211586D0 (en) Japanese cedar peptides for preventing or treating allergy
吴雪莲 Let’s live in a world full of understanding!

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 OCT 2016 BY FB RICE

Effective date: 20131018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2017 BY RENEWALS TEAM

Effective date: 20161018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2018 BY RENEWALS TEAM

Effective date: 20171012

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2019 BY SERVICE TEAM

Effective date: 20180730

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2020 BY RENEWALS TEAM

Effective date: 20191017

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2021 BY RENEWALS TEAM

Effective date: 20201019

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2022 BY RENEWALS TEAM

Effective date: 20211023

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2023 BY ENVOY

Effective date: 20221014

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2024 BY ANAQUA SERVICES

Effective date: 20230921

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2025 BY ANAQUA SERVICES

Effective date: 20240920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2026 BY ANAQUA SERVICES

Effective date: 20250924